GLUE (Monte Rosa Therapeutics) Total Receivables: $4.61 Mil (As of Mar. 2026)


GLUE Monte Rosa Therapeutics Inc GLUE
34 GF Score
Price $23.02
! 5 Warning Signs
View Full Analysis

What is Monte Rosa Therapeutics Total Receivables?

Monte Rosa Therapeutics GLUE -6.04% 34 Total Receivables is $4.61 Mil as of Mar. 2026. GuruFocus rates GLUE with a GF Score™ of 34/100. The stock has 5 warning signs investors should review.

Monte Rosa Therapeutics's Total Receivables for the quarter that ended in Mar. 2026 was $4.61 Mil.

Monte Rosa Therapeutics Total Receivables Related Terms

Monte Rosa Therapeutics Total Receivables Historical Data

* Premium members only.

The historical data trend for Monte Rosa Therapeutics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monte Rosa Therapeutics Total Receivables Chart

Monte Rosa Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial 0.00 7.66 0.51 0.17 11.60

Monte Rosa Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.41 2.37 4.97 11.60 4.61
GLUE
34GF Score
Monte Rosa Therapeutics Inc GLUE
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monte Rosa Therapeutics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $4.61 Mil mean?
Monte Rosa Therapeutics (GLUE) has a Total Receivables of $4.61 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Monte Rosa Therapeutics and its competitors.
Is Monte Rosa Therapeutics' Total Receivables too high?
Monte Rosa Therapeutics' current Total Receivables is $4.61 Mil. Overall, Monte Rosa Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Monte Rosa Therapeutics' Total Receivables compare to SNDX and IOVA?
Monte Rosa Therapeutics' Total Receivables of $4.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Monte Rosa Therapeutics and its competitors. Monte Rosa Therapeutics's current Total Receivables is $4.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monte Rosa Therapeutics stock overvalued right now?
Monte Rosa Therapeutics (GLUE) has a current Total Receivables of $4.61 Mil. The current Total Receivables is $4.61 Mil. Monte Rosa Therapeutics' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Monte Rosa Therapeutics (GLUE), the current Total Receivables is $4.61 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monte Rosa Therapeutics Business Description

Address 321 Harrison Avenue, Suite 900, Boston, MA, USA, 02118
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
34GF Score

Get the complete analysis for GLUE

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.02
Price